Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Impact · against what's priced in

RANI is significantly re-rated upward following a billion-dollar partnership with Chugai, a critical capital infusion via private placement, and the clinical initiation of an oral GLP-1/GLP-2 dual agonist. For 4523, the collaboration is a strategic expansion into oral biologic delivery but represents a smaller proportional impact on its overall valuation.

RANI+1.00

No priced-in read yet